CYP1A1 and CYP1B1 polymorphism and lung cancer risk in relation to tobacco smoking

Cancer Genomics and Proteomics

Volumn 1, Issue 2, 2004, Pages 189-198

  Schneider, Joachim ^a   Bernges, Ulrike ^a   Philipp, Monika ^a   Woitowitz, Hans Joachim ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

CYP1A1 A4889G; CYP1A1 T6235C; CYP1B1 polymorphisms; Lung cancer; Susceptibility; Tobacco smoking

Indexed keywords

EID: 39249083755     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Guengerich FP and Shimada T: Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 4: 391-407, 1990.
2. Omiecinski CJ, Redlich CA and Costa P: Induction and developmental expression of cytochrome P4501A1 messenger RNA in rat and human tissue: detection by the polymerase chain reaction. Cancer Res 50: 4315-4321, 1990.
3. McManus ME, Burgess WM, Veronese ME, Huggett A, Quatrocchi LC and Tukey RH: Metabolism of 2-acetylaminofluorene and benzo()pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome p450. Cancer Res 50: 3367-3376, 1990.
4. Nebert DW, Ingelman-Sundberg M and Daly AK: Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metabol Rev 31: 467-487, 1999.
5. Bartsch H, Nair U, Risch A, Rojas M, Wikman H and Alexandrov K: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9: 3-28, 2000.
6. Cascorbi I, Brockmoller J and Roots I: C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56: 4965-4969, 1996.
7. Puga A, Nebert DW, McKinnon RA and Menon AG: Genetic polymorphisms in human drug-metabolising enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 27: 199-222, 1997.
8. Landi MT, Bertazzi PA; Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G and Caporaso NE: Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4: 242-246, 1994.
9. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N and Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of cytochrome P4501A1 gene. FEBS Lett 263: 131-133, 1990.
10. Li DN, Seidel A, Pritchard MP, Wolf CR and Friedberg T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmocogenetics 10: 343-353, 2000.
11. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O and Kawajiri K: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmocogenetics 10: 25-33, 2000.
12. Harth V, Brüning T, Abel J, Koch B, Berg I, Sachinidis A, Bolt HM, Vetter H and Ko Y: Real-time genotyping of cytochrome P4501A1 A 4889G and T6235C polymorphisms. Molecular Cellular Probes 15: 93-97, 2001.
13. Brüning T, Abel J, Koch B, Lorenzen K, Harth V, Donat S, Sachinidis A, Vetter H, Bolt HM and Ko Y: Real time PCRanalysis of the cytochrome P4501B1 codon 432-polymorphism. Arch Toxicol 73: 427-430, 1999.
14. Fritsche E, Brüning T, Jonkmans C, Ko Y, Bolt HM and Abel J: Detection of cytochrome P450 1B1 BfrI polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics 9: 405-408, 1999.
15. Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Aldersea J, Gilford J, Bailey L, Barth J, Worrall SF, Hand P, Fryer AA and Strange RC: Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmocogenetics 8: 91-100, 1998.
16. Bartsch H, Rojas M, Alexandrov K and Risch A: Impact of adduct determination an assessment of cancer susceptibility. Recent Results Cancer Res 154: 86-96, 1998.
17. Mooney LA, bell DA, Santella RM, vanBennekum AM, Ottman R, Paik M, Blaner WS, Lucier GW, Covey L, Young TL, Cooper TB, Glassman AH and Perera FP: Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18: 503-509, 1997.
18. Xu X, Kelsey KT, Wiencke JK, Wain JC and Christiani DC: Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5: 687-692, 1996.
19. Gsur A, Haidinger G, Hollaus P, Herbacek I, Madersbacher S, Treib K, Pridun N, Mohn-Staudner A, Vetter N, Vutuc C and Micksche M: Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk. Anticancer Res 21: 2237-2242, 2001.
20. Carstensen U, Alexandrie AK, Hogstedt B, Rannug A, Bratt I and Hagmar L: B-and T-lymphocyte micronuclei in chimney sweeps with respect to genetic polymorphism for CYP1A1 and GST1 (class Mu). Mutat Res 289: 187-195, 1993.
21. Kelsey KT, Wiencke JK, Xu X, Wain JC and Christiani DC: A case-control study of cytochrome P450 1A1, glutathione Stransferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 8: 544-553, 1997.
22. LeMarchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR and Lau AF: Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58: 4858-4863, 1998.
23. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A and Borresen AL: Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1: 20-25, 1991.
24. London SJ, Daly AK, Faibrother KS, Holmes C, Carpenter CL, Navidi WC and Idle JR: Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res 55: 6035-6037, 1995.
25. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, Hoover RN, Weston A and Harris CC: Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2: 481-485, 1993.
26. Nakachi K, Imai, K, Hayashi S and Kawajiri K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994-2999, 1993.
27. Hayashi S, Watanabe J and Kawajiri K: High susceptibility to lung cancer analysed in term of combined genotypes of CYP1A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83: 866-870, 1992.
28. Hirvonen A, Pursianen KH, Karjalaienen A, Antilla S and Vainio H: Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1: 485-489, 1992.
29. Ko Y, Koch B, Harth V, Sachinidis A, Thier R, Vetter H, Bolt HM and Brüning T: Rapid analysis of GSTM1, GSTT1 and GSTP1 polymorphisms using real-time polymerase chain reaction. Pharmacogenetics 10: 271-274, 2000.
30. Raunio H, Husgafvel-Pursiainen, Anttiula S, Hietanen E, Hirvonen A and Pelkonen O: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 159: 113-121, 1995.
31. Drakoulis N, Cascorbi I, Brockmüller J, Gross CR and Roots I: Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig 72: 240-248, 1994.
32. Wu X, Shi H, Jing H, Kemp B, Hong WK, Delclos GL and Spitz MR: Association between cytochrome P450E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 18: 967-973, 1997.